Home - References


+30 years of experience in clinical studies and research

For more than 30 years, our center has conducted a variety of studies in different therapeutic indications but especially specialized in disorders of the brain.

Through the expansion of our facilities, first in 2017 and then in 2021 with now 2 fully equipped sites on the one hand at Alken (Alkerstraat 28-30-30A-32Z) and on the other hand at Diepenbeek (Wetenschapspark 11-13), ARC currently has a very extensive clinical research facility, meeting the most stringent international requirements.

Including a day and overnight accommodation for 12 people which allows to perform intensive PK sampling as well as other demanding clinical evaluations such as poly-somnography (PSG), Anima Research Center can perform the most demanding Phase 0 to Phase IV studies .

Interested in a cooperation?


Current participants in clinical trial


Qualified patients in our database


Strategic collaborations with internationally active pharma companies


Top researchers


+50 Clinical studies

1989-1990: Phase III trial investigating mianserine

2000-2001: Phase III trial investigating agomelatine

2001-2002: phase III trial investigating escitalopram

2003-2005: phase III and 1 phase IIb trial: several NK1-Antagonists

2006-2013: 5 phase I trials, 1 phase II trial and 1 phase III trial investigating PNB01

2014- ongoing:

  • 3 Phase III trials & 1 Phase IV trial investigating esketamine in Treatment Resistant Depression, 1 Recruitment still ongoing.
  • 2 Phase 0 bio-marker study in healthy volunteers and depressed patients with and without intake of antidepressants.
  • 1 Phase I trial investigating impact of seltoxerant on driving capabilities. Highest recruiter wordwide. Successfully audited by sponsor Janssen Pharmaceutica.
  • 1 Phase III trials investigating aticaprant as adjunctive treatment in Major Depression.

1991-1992: phase IIa trial investigating cycloserine in cognitive impairment

2020 - ongoing: Phase I On Road Driving Study investigating cognitive impact of seltorexant in patients with Major Depressive Disorder. Recruitment Ongoing.

2021: Phase 0 bio-marker study in patients with a neurodegenerative disorder

2022: Phase IIa study in neuro-degeneration in Mild Cognitive Impairment, Parkinson's and Alzheimer's Disease

1987-1988: phase III trial investigating Risperidone

2004: phase III trial investigating aripiprazole

2006-2007: phase III trial investigating asenapine

2013: phase IIa trial investigating PNB02 in treatment resistant schizophrenia

2004-2005: phase IIb trial investigating gaboxadol in primary insomnia.

2018-2019: phase IIb trial investigating seltorexant including PSG and cognitive test battery assessments. Highest recruiter in Belgium. Successfully audited by the sponsor Janssen Pharmaceutica.

2019-2020: Phase III clinical study investigating JZP-080 in idiopathic hypersomnia including specialized narcotics handling & PSG and MSLT assessments. Highest recruiter of Europe. Successfully audited by the sponsor Jazz Pharmaceuticals.

2022 - ongoing: Phase II clinical study investigating undisclosed compound in Obstructive Sleep Apnea. Highest Recruiter worldwide.

1993-1994: Phase III trial investigating sertraline in obsessive-compulsive disorder

2021 - ongoing: Phase 0 bio-marker study in PTSD patients with and without intake of psychotropics

2021 - ongoing: Phase 0 bio-marker study in bipolar patients with and without intake of psychotropics

2020 - ongoing: 3 Phase III trial investigating antibody treatment to prevent COVID-19 infection in high risk and elderly population. Recruitment ongoing.

2020 - ongoing: 3 phase III trial investigating vaccine to prevent COVID-19 infections. Highest recruiter worldwide in one key study.

2020 - 2022: phase I/IIA trial investigating vaccine to prevent septic shock in patients with medical history of UTI. Recruitment closed. Highest recruiter!

2021 - ongoing: 3 phase I-III trials investigating vaccine to prevent RSV infections. Recruitment closed. Highest recruiter in Belgium.

2022 - ongoing: Phase III trials investigating an innovative pneumococcal vaccine. Highest recruiter worldwide.

2023 - planned: Fist in Human Study with innovative HPV vaccine (selected).

2023 - planned: Phase II-III clinical trial with innovative meningococcal vaccine (selected).

2022 - ongoing: Phase I clincal trial with innovative immunoregulating compound for treatment of atopic dermatitis. Highest recruiter worldwide.

2022-ongoing: Phase I Safety & Pharmaco-dynamic clincal trial, including high end imaging (MRI, US) with innovative combination drug in prevention of sarcopenia. Selected as single study center for this very high demanding clincal study.

  • Healthy Volunteers & Major Depression (2)
  • PTSD (1)
  • Bipolar Disorder (1)
  • Neurodegeneration (1)
  • Major Depression (6)
  • Neurodegeneration (1)
  • RSV (1)
  • Atopic Dermatitis (1)
  • Sarcopenia (1)
  • Cognitive Decline (4)
  • Major Depression (2)
  • Sleep Disorder (3)
  • Psychosis (1)
  • Vaccination (3)
  • Major Depression (9)
  • Psychosis (3)
  • Cognitive Decline (1)
  • Hypersomnia (1)
  • COVID-19 (6)
  • RSV & Other Vaccines (6)
Our pharmaceutical partners

Working together for a better world